CapMan acquires 45% stake in Russia's Medisorb

Financial details were not disclosed. Capital was drawn from CapMan's Russia II fund, which structured a round of growth funding to back the drug manufacturer in July 2017.

Russian newspaper Vedomosti reported the 45% stake to be valued in the region of RUB 1bn. General director Vladimir Foteev will own the remaining 55% stake.

CapMan's Russia II fund held a final close in September 2014 on €99m after an initial target was set at €175m. The GP's previous Russian fund held a final close on €118m. The fund backs sectors that target Russia's growing middle class, including consumer goods and services, e-commerce, home improvement, business services and private healthcare.

Company
Founded in 1993, Medisorb manufactures generic drugs. Its products include pharmacotherapeutic groups such as analgetics, analgesics, spasmolytics and enterosorbents. The company is based in Perm, Russia, with an additional office in Moscow. It has 500 employees. The company posted a turnover of RUB 727m in 2016.

People
CapMan – Hans Christian Dall Nygård (managing partner).
Medisorb – Vladimir Foteev (general director).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Healthcare
• CEE
• Russia
• CapMan